Press Releases | Investor Relations

Year

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the first quarter ended March 31, 2023.

May 05, 2023

PDF Version

Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that its pre-clinical manuscript entitled “Oral Delivery Technology Enabling Gastro-Mucosal

May 03, 2023

PDF Version

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board

JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University

Apr 26, 2023

PDF Version

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced feedback from its Type D Meeting with the U.S. Food and Drug Administration (FDA) related to

Apr 03, 2023

PDF Version

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced a summary of 2022 corporate achievements and financial results for the year ended December 31,

Mar 31, 2023

PDF Version

Entera Bio Regains Compliance with Nasdaq Listing Requirements

JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 23, 2023, informing

Mar 23, 2023

PDF Version

Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023 JERUSALEM, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of

Feb 15, 2023

PDF Version

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will participate in the SVB Securities Global Biopharma

Feb 13, 2023

PDF Version